Prospective study of NEOadjuvant Anastrozole and RadioTherapy for hormone-responsive postmenopausal breast cancer (NEO-A-RT)

INTERVENTION: Patients will receive anastrozole 1mg daily for 24 weeks and receive radiotherapy (50Gy / 25 fr) at 13 weeks from the start of anastrozole. Patients will receive surgery at 24 weeks. CONDITION: early breast cancer PRIMARY OUTCOME: Clinical response rate INCLUSION CRITERIA: 1) Postmenopausal patients with biopsy‐proven invasive breast cancer 2) TNM classification: T2 (3cm and larger)‐T4, N0‐2, M0 3) ER‐positive tumor (10% or more positively staining by immunohistochemistry) 4) PS (ECOG): 0 or 1 5) Normal bone marrow, liver and renal function 6) Patients who have never received any treatment for breast cancer 7) Written informed consent is obtained